Reported Earnings • May 15
Full year 2026 earnings released: JP¥79.72 loss per share (vs JP¥8.65 profit in FY 2025) Full year 2026 results: JP¥79.72 loss per share (down from JP¥8.65 profit in FY 2025). Revenue: JP¥40.3b (down 11% from FY 2025). Net loss: JP¥9.60b (down JP¥10.6b from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance. Announcement • May 09
Takara Bio Inc. to Report Fiscal Year 2026 Results on May 13, 2026 Takara Bio Inc. announced that they will report fiscal year 2026 results on May 13, 2026 New Risk • Apr 15
New major risk - Revenue and earnings growth Earnings have declined by 48% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 48% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). Announcement • Apr 08
Takara Holdings Inc. (TSE:2531) completed the acquisition of remaining 26.35% stake in Takara Bio Inc. (TSE:4974) from group of shareholders for ¥36.4 billion. Takara Holdings Inc. (TSE:2531) proposed to acquire remaining 39.09% stake in Takara Bio Inc. (TSE:4974) from group of shareholders for ¥54.1 billion on February 13, 2026. Under the terms of the acquisition, Takara Holdings Inc. will pay ¥1150 in cash per share. The tender offer will commence on February 16, 2026 and will close on April 6, 2026. Upon completion of the Tender Offer, if Takara Holdings Inc holds in aggregate of 90% or more, squeeze-out procedure will be launched. Upon completion, Takara Holdings Inc. will own 100% stake in Takara Bio Inc and shares will be delisted from the Prime Market of the TSE.
The transaction is subject to minimum tender and approval by the shareholders of Takara Bio Inc. The expected completion of the transaction is April 6, 2026.
Takara Holdings Inc. (TSE:2531) completed the acquisition of remaining 26.35% stake in Takara Bio Inc. (TSE:4974) from group of shareholders for ¥36.4 billion on April 6, 2026. New Risk • Feb 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change). Reported Earnings • Feb 14
Third quarter 2026 earnings released: JP¥22.49 loss per share (vs JP¥15.70 loss in 3Q 2025) Third quarter 2026 results: JP¥22.49 loss per share (further deteriorated from JP¥15.70 loss in 3Q 2025). Revenue: JP¥9.60b (flat on 3Q 2025). Net loss: JP¥2.71b (loss widened 43% from 3Q 2025). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Announcement • Dec 27
Takara Bio Inc. to Report Q3, 2026 Results on Feb 13, 2026 Takara Bio Inc. announced that they will report Q3, 2026 results on Feb 13, 2026 Major Estimate Revision • Dec 23
Consensus EPS estimates fall by 242% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from JP¥46.3b to JP¥44.4b. Losses expected to increase from JP¥12.31 per share to JP¥42.05. Biotechs industry in Japan expected to see average net income growth of 10% next year. Consensus price target down from JP¥1,220 to JP¥1,157. Share price was steady at JP¥781 over the past week. Reported Earnings • Nov 13
Second quarter 2026 earnings released: JP¥44.85 loss per share (vs JP¥12.96 profit in 2Q 2025) Second quarter 2026 results: JP¥44.85 loss per share (down from JP¥12.96 profit in 2Q 2025). Revenue: JP¥9.53b (down 15% from 2Q 2025). Net loss: JP¥5.40b (down 446% from profit in 2Q 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Announcement • Sep 02
Takara Bio Inc. to Report Q2, 2026 Results on Nov 11, 2025 Takara Bio Inc. announced that they will report Q2, 2026 results on Nov 11, 2025 Reported Earnings • Aug 09
First quarter 2026 earnings released: JP¥12.55 loss per share (vs JP¥8.70 loss in 1Q 2025) First quarter 2026 results: JP¥12.55 loss per share (further deteriorated from JP¥8.70 loss in 1Q 2025). Revenue: JP¥9.27b (up 9.1% from 1Q 2025). Net loss: JP¥1.51b (loss widened 44% from 1Q 2025). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Board Change • Jul 11
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. 3 independent directors (6 non-independent directors). Independent External Director Noriomi Matsumura was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Jun 25
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: JP¥8.65 (down from JP¥12.29 in FY 2024). Revenue: JP¥45.0b (up 3.5% from FY 2024). Net income: JP¥1.04b (down 30% from FY 2024). Profit margin: 2.3% (down from 3.4% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Jun 13
Consensus EPS estimates fall by 24% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from JP¥49.5b to JP¥48.1b. EPS estimate also fell from JP¥35.34 per share to JP¥26.89 per share. Net income forecast to grow 211% next year vs 9.3% growth forecast for Biotechs industry in Japan. Consensus price target down from JP¥1,267 to JP¥1,193. Share price was steady at JP¥782 over the past week. Announcement • Jun 10
Takara Bio Inc. to Report Q1, 2026 Results on Aug 08, 2025 Takara Bio Inc. announced that they will report Q1, 2026 results on Aug 08, 2025 Reported Earnings • May 14
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: JP¥8.65 (down from JP¥12.29 in FY 2024). Revenue: JP¥45.0b (up 3.5% from FY 2024). Net income: JP¥1.04b (down 30% from FY 2024). Profit margin: 2.3% (down from 3.4% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Announcement • May 13
Takara Bio Inc., Annual General Meeting, Jun 24, 2025 Takara Bio Inc., Annual General Meeting, Jun 24, 2025. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥17.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 June 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.1%). Announcement • Mar 12
Takara Bio Inc. to Report Fiscal Year 2025 Results on May 13, 2025 Takara Bio Inc. announced that they will report fiscal year 2025 results on May 13, 2025 Price Target Changed • Mar 12
Price target decreased by 14% to JP¥1,267 Down from JP¥1,467, the current price target is an average from 3 analysts. New target price is 50% above last closing price of JP¥842. Stock is down 16% over the past year. The company is forecast to post earnings per share of JP¥1.90 for next year compared to JP¥12.29 last year. Reported Earnings • Feb 15
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: JP¥15.70 loss per share (further deteriorated from JP¥7.72 loss in 3Q 2024). Revenue: JP¥9.52b (down 10% from 3Q 2024). Net loss: JP¥1.89b (loss widened 103% from 3Q 2024). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 162%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. New Risk • Feb 14
New minor risk - Dividend sustainability The dividend is not well covered by earnings. Payout ratio: 225% Dividend yield: 1.9% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (225% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Announcement • Jan 17
Takara Bio Inc. to Report Q3, 2025 Results on Feb 13, 2025 Takara Bio Inc. announced that they will report Q3, 2025 results on Feb 13, 2025 Declared Dividend • Nov 11
Dividend of JP¥17.00 announced Dividend of JP¥17.00 is the same as last year. Ex-date: 28th March 2025 Payment date: 24th June 2025 Dividend yield will be 1.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (225% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 30% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 150% to bring the payout ratio under control. EPS is expected to grow by 96% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Reported Earnings • Nov 09
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: JP¥12.96 (up from JP¥6.35 in 2Q 2024). Revenue: JP¥11.3b (up 13% from 2Q 2024). Net income: JP¥1.56b (up 104% from 2Q 2024). Profit margin: 14% (up from 7.7% in 2Q 2024). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance. Announcement • Aug 29
Takara Bio Inc. to Report Q2, 2025 Results on Nov 08, 2024 Takara Bio Inc. announced that they will report Q2, 2025 results on Nov 08, 2024 Reported Earnings • Aug 09
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: JP¥8.70 loss per share (down from JP¥2.65 profit in 1Q 2024). Revenue: JP¥8.49b (down 7.4% from 1Q 2024). Net loss: JP¥1.05b (down 428% from profit in 1Q 2024). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 93%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to JP¥947, the stock trades at a forward P/E ratio of 31x. Average trailing P/E is 55x in the Biotechs industry in Japan. Total loss to shareholders of 66% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,815 per share. Announcement • Jun 14
Takara Bio Inc. to Report Q1, 2025 Results on Aug 08, 2024 Takara Bio Inc. announced that they will report Q1, 2025 results on Aug 08, 2024 Reported Earnings • May 12
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: JP¥12.29 (down from JP¥133 in FY 2023). Revenue: JP¥43.5b (down 44% from FY 2023). Net income: JP¥1.48b (down 91% from FY 2023). Profit margin: 3.4% (down from 21% in FY 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) also missed analyst estimates by 28%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 30% per year. Major Estimate Revision • May 11
Consensus EPS estimates fall by 30% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from JP¥47.4b to JP¥46.9b. EPS estimate also fell from JP¥31.01 per share to JP¥21.80 per share. Net income forecast to grow 100% next year vs 18% growth forecast for Biotechs industry in Japan. Consensus price target down from JP¥1,600 to JP¥1,567. Share price was steady at JP¥1,025 over the past week. Major Estimate Revision • Apr 14
Consensus EPS estimates fall by 56% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥48.7b to JP¥44.8b. EPS estimate also fell from JP¥38.47 per share to JP¥17.10 per share. Net income forecast to grow 112% next year vs 12% growth forecast for Biotechs industry in Japan. Consensus price target down from JP¥1,867 to JP¥1,600. Share price was steady at JP¥967 over the past week. Price Target Changed • Apr 12
Price target decreased by 17% to JP¥1,600 Down from JP¥1,933, the current price target is an average from 3 analysts. New target price is 65% above last closing price of JP¥967. Stock is down 45% over the past year. The company is forecast to post earnings per share of JP¥17.10 for next year compared to JP¥133 last year. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥17.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.7%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (1.2%). Announcement • Mar 18
Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD) Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD) Announcement • Mar 14
Takara Bio Inc. to Report Fiscal Year 2024 Results on May 10, 2024 Takara Bio Inc. announced that they will report fiscal year 2024 results on May 10, 2024 Reported Earnings • Feb 16
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: JP¥7.72 loss per share (down from JP¥50.30 profit in 3Q 2023). Revenue: JP¥10.6b (down 62% from 3Q 2023). Net loss: JP¥930.0m (down 115% from profit in 3Q 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. Major Estimate Revision • Feb 15
Consensus EPS estimates increase by 29%, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from JP¥49.4b to JP¥48.7b. EPS estimate rose from JP¥39.74 to JP¥51.35. Net income forecast to shrink 31% next year vs 1.0% decline forecast for Biotechs industry in Japan. Consensus price target down from JP¥1,933 to JP¥1,867. Share price fell 15% to JP¥1,024 over the past week. Announcement • Dec 01
Takara Bio Inc. to Report Q3, 2024 Results on Feb 14, 2024 Takara Bio Inc. announced that they will report Q3, 2024 results on Feb 14, 2024 Major Estimate Revision • Nov 28
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥51.5b to JP¥49.4b. EPS estimate also fell from JP¥46.71 per share to JP¥39.74 per share. Net income forecast to shrink 35% next year vs 35% growth forecast for Biotechs industry in Japan . Consensus price target down from JP¥2,200 to JP¥1,933. Share price was steady at JP¥1,214 over the past week. Price Target Changed • Nov 27
Price target decreased by 17% to JP¥1,933 Down from JP¥2,333, the current price target is an average from 3 analysts. New target price is 59% above last closing price of JP¥1,213. Stock is down 34% over the past year. The company is forecast to post earnings per share of JP¥50.50 for next year compared to JP¥133 last year. Announcement • Nov 12
Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024 Takara Bio Inc. revised consolidated earnings guidance for the year ending March 31, 2024. For the year ending March 31, 2024, the company expects net sales of JPY 45,500 million compared to previous guidance of JPY 53,300 million, operating profit of JPY 3,000 million compared to previous guidance of JPY 8,000 million and net income attributable to owners of parent of JPY 2,000 million or JPY 16.61 per share compared to previous guidance of JPY 5,500 million or JPY 45.67 per share. Reported Earnings • Nov 10
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: JP¥6.35 (down from JP¥38.46 in 2Q 2023). Revenue: JP¥9.94b (down 46% from 2Q 2023). Net income: JP¥765.0m (down 84% from 2Q 2023). Profit margin: 7.7% (down from 25% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) also missed analyst estimates by 2.2%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Buying Opportunity • Sep 20
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be JP¥1,758, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.8% per annum. Earnings is also forecast to grow by 4.4% per annum over the same time period. Announcement • Sep 02
Takara Bio Inc. to Report Q2, 2024 Results on Nov 09, 2023 Takara Bio Inc. announced that they will report Q2, 2024 results on Nov 09, 2023 Buying Opportunity • Aug 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be JP¥1,758, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 4.3% per annum over the same time period. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to JP¥1,411, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 29x in the Biotechs industry in Asia. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,758 per share. Reported Earnings • Aug 09
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: EPS: JP¥2.65 (down from JP¥32.45 in 1Q 2023). Revenue: JP¥9.18b (down 35% from 1Q 2023). Net income: JP¥319.0m (down 92% from 1Q 2023). Profit margin: 3.5% (down from 28% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Jun 21
Takara Bio Inc. to Report Q1, 2024 Results on Aug 08, 2023 Takara Bio Inc. announced that they will report Q1, 2024 results on Aug 08, 2023 Reported Earnings • May 16
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: JP¥133 (down from JP¥165 in FY 2022). Revenue: JP¥78.1b (up 15% from FY 2022). Net income: JP¥16.0b (down 19% from FY 2022). Profit margin: 21% (down from 29% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 8.9%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to stay flat during the next 3 years compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • May 12
Takara Bio Inc., Annual General Meeting, Jun 23, 2023 Takara Bio Inc., Annual General Meeting, Jun 23, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥42.00 per share at 2.3% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.0%). Reported Earnings • Feb 10
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: JP¥50.30 (up from JP¥36.17 in 3Q 2022). Revenue: JP¥27.6b (up 96% from 3Q 2022). Net income: JP¥6.06b (up 39% from 3Q 2022). Profit margin: 22% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 71%. Earnings per share (EPS) also surpassed analyst estimates by 136%. Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Japan are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Dec 23
Takara Bio Inc. to Report Q3, 2023 Results on Feb 09, 2023 Takara Bio Inc. announced that they will report Q3, 2023 results on Feb 09, 2023 Price Target Changed • Nov 29
Price target decreased to JP¥2,250 Down from JP¥2,450, the current price target is an average from 4 analysts. New target price is 24% above last closing price of JP¥1,813. Stock is down 31% over the past year. The company is forecast to post earnings per share of JP¥113 for next year compared to JP¥165 last year. Reported Earnings • Nov 16
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: JP¥38.46 (up from JP¥33.09 in 2Q 2022). Revenue: JP¥18.5b (up 14% from 2Q 2022). Net income: JP¥4.63b (up 16% from 2Q 2022). Profit margin: 25% (in line with 2Q 2022). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Japan are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent External Director Noriomi Matsumura was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: JP¥38.46 (up from JP¥33.09 in 2Q 2022). Revenue: JP¥18.5b (up 14% from 2Q 2022). Net income: JP¥4.63b (up 16% from 2Q 2022). Profit margin: 25% (in line with 2Q 2022). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Japan are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 06
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2023 results: EPS: JP¥32.45 (down from JP¥50.04 in 1Q 2022). Revenue: JP¥14.1b (down 7.7% from 1Q 2022). Net income: JP¥3.91b (down 35% from 1Q 2022). Profit margin: 28% (down from 40% in 1Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 6.4%. Over the next year, revenue is expected to shrink by 12% compared to a 180% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Price Target Changed • Jul 11
Price target decreased to JP¥2,400 Down from JP¥2,678, the current price target is an average from 4 analysts. New target price is 21% above last closing price of JP¥1,985. Stock is down 31% over the past year. The company is forecast to post earnings per share of JP¥109 for next year compared to JP¥165 last year. Price Target Changed • May 19
Price target decreased to JP¥2,515 Down from JP¥2,832, the current price target is an average from 5 analysts. New target price is 36% above last closing price of JP¥1,852. Stock is down 37% over the past year. The company is forecast to post earnings per share of JP¥100 for next year compared to JP¥165 last year. Reported Earnings • May 14
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: JP¥165 (up from JP¥79.28 in FY 2021). Revenue: JP¥67.7b (up 47% from FY 2021). Net income: JP¥19.8b (up 108% from FY 2021). Profit margin: 29% (up from 21% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.6%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 16% compared to a 217% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent External Director Noriomi Matsumura was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥30.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 25 June 2022. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (0.6%). Major Estimate Revision • Feb 18
Consensus revenue estimates increase by 16% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from JP¥56.3b to JP¥65.5b. EPS estimate increased from JP¥112 to JP¥158 per share. Net income forecast to shrink 25% next year vs 37% growth forecast for Biotechs industry in Japan . Consensus price target broadly unchanged at JP¥2,742. Share price rose 3.0% to JP¥2,368 over the past week. Price Target Changed • Feb 17
Price target decreased to JP¥2,742 Down from JP¥3,012, the current price target is an average from 5 analysts. New target price is 16% above last closing price of JP¥2,368. Stock is down 25% over the past year. The company is forecast to post earnings per share of JP¥158 for next year compared to JP¥79.28 last year. Reported Earnings • Feb 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: JP¥36.17 (up from JP¥28.67 in 3Q 2021). Revenue: JP¥14.1b (up 16% from 3Q 2021). Net income: JP¥4.36b (up 26% from 3Q 2021). Profit margin: 31% (up from 28% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) also surpassed analyst estimates by 78%. Over the next year, revenue is expected to shrink by 14% compared to a 1,826% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Price Target Changed • Nov 26
Price target decreased to JP¥2,792 Down from JP¥3,232, the current price target is an average from 5 analysts. New target price is 5.3% above last closing price of JP¥2,651. Stock is down 10% over the past year. The company is forecast to post earnings per share of JP¥112 for next year compared to JP¥79.28 last year. Price Target Changed • Nov 17
Price target decreased to JP¥3,012 Down from JP¥3,332, the current price target is an average from 5 analysts. New target price is 10% above last closing price of JP¥2,728. Stock is down 7.0% over the past year. The company is forecast to post earnings per share of JP¥110 for next year compared to JP¥79.28 last year. Reported Earnings • Nov 10
Second quarter 2022 earnings released: EPS JP¥33.09 (vs JP¥15.53 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥16.3b (up 56% from 2Q 2021). Net income: JP¥3.98b (up 113% from 2Q 2021). Profit margin: 25% (up from 18% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Aug 19
Consensus EPS estimates increase to JP¥91.00 The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from JP¥50.8b to JP¥52.0b. EPS estimate increased from JP¥78.12 to JP¥91.00 per share. Net income forecast to shrink 30% next year vs 45% growth forecast for Biotechs industry in Japan . Consensus price target broadly unchanged at JP¥3,292. Share price was steady at JP¥2,981 over the past week. Reported Earnings • Aug 05
First quarter 2022 earnings released: EPS JP¥50.04 (vs JP¥3.36 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥15.3b (up 120% from 1Q 2021). Net income: JP¥6.03b (up JP¥5.62b from 1Q 2021). Profit margin: 40% (up from 5.8% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 15
Full year 2021 earnings released: EPS JP¥79.28 (vs JP¥31.72 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥46.1b (up 33% from FY 2020). Net income: JP¥9.55b (up 150% from FY 2020). Profit margin: 21% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥14.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 24 June 2021. Trailing yield: 0.5%. Lower than top quartile of Japanese dividend payers (2.7%). In line with average of industry peers (0.5%). Major Estimate Revision • Feb 24
Analysts increase EPS estimates to JP¥53.65 The 2021 consensus revenue estimate increased from JP¥40.1b to JP¥41.9b. The earnings per share estimate also received an upgrade from JP¥46.92 to JP¥53.65 for the same period. Net income is expected to shrink by 2.2% next year compared to 57% growth forecast for the Biotechs industry in Japan . The consensus price target increased from JP¥3,143 to JP¥3,227. Share price is down by 8.6% to JP¥2,961 over the past week. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS JP¥28.67 (vs JP¥5.26 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥12.2b (up 50% from 3Q 2020). Net income: JP¥3.45b (up 445% from 3Q 2020). Profit margin: 28% (up from 7.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 02
New 90-day high: JP¥3,045 The company is up 7.0% from its price of JP¥2,833 on 04 November 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥1,728 per share. Is New 90 Day High Low • Dec 22
New 90-day low: JP¥2,752 The company is down 6.0% from its price of JP¥2,940 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥1,744 per share. Is New 90 Day High Low • Dec 03
New 90-day high: JP¥3,020 The company is up 7.0% from its price of JP¥2,813 on 04 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥1,530 per share. 
